Our Science

Leveraging adaptive immune responses to destroy cancerous cells

Scancell targets modifications of proteins and lipids prevalent in cancer to generate potent anti-tumour responses by harnessing the adaptive immune response.

Active Immunotherapies

ImmunoBody®

ImmunoBody® DNA active immunotherapies encode a protein in the form of a modified antibody, which is engineered to express epitopes from a cancer antigen whilst retaining the ability to target activated antigen presenting cells in vivo.

See more

Moditope®

The Moditope® platform is a unique class of potent, peptide active immunotherapies targeting tumour-specific neoantigens via the MHC-II presentation pathway.

See more

Antibodies

Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, as well as AvidiMab® Fc engineering to improve the avidity of antibodies.

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.